Health
Triggering tumor antiviral immune response in triple negative breast cancer – EurekAlert
Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast…
HOUSTON – (Jan. 14, 2021) – Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell death and signal the body’s immune response. A new study published in Cell shows that endogenous mis-spliced RNA in tumor cells mimics an RNA virus, leading tumor cells to self-destruct as if fighting an infection. Researchers suggest this mechanism could open new avenues…
-
Noosa News20 hours agoHow Lily Steele-Park took her rapist to court and won
-
Noosa News23 hours agoStar’s Brisbane casino has been in the headlines for months: What’s the latest?
-
Business22 hours ago5 things to watch on the ASX 200 on Tuesday 8 July 2025
-
Noosa News20 hours agoE-biker charged with riding dangerously, assaulting cop